Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) Price Target at $14.85

Hims & Hers Health, Inc. (NYSE:HIMS) has earned a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $15.07.

A number of equities analysts have commented on HIMS shares. Truist Financial boosted their target price on shares of Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a report on Tuesday, February 27th. Citigroup boosted their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Seaport Res Ptn restated a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Piper Sandler upped their price objective on shares of Hims & Hers Health from $11.00 to $13.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, Canaccord Genuity Group initiated coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective on the stock.

Insiders Place Their Bets

In other Hims & Hers Health news, COO Melissa Baird sold 11,750 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total transaction of $141,940.00. Following the completion of the transaction, the chief operating officer now directly owns 538,932 shares of the company’s stock, valued at approximately $6,510,298.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $12.54, for a total transaction of $2,368,655.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Melissa Baird sold 11,750 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total transaction of $141,940.00. Following the sale, the chief operating officer now directly owns 538,932 shares in the company, valued at approximately $6,510,298.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 736,191 shares of company stock valued at $9,733,700. 31.63% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC acquired a new stake in Hims & Hers Health in the 4th quarter valued at $48,000. Cornerstone Investment Partners LLC acquired a new stake in Hims & Hers Health in the 1st quarter valued at $161,000. EMC Capital Management grew its stake in Hims & Hers Health by 80.0% in the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000 after acquiring an additional 5,332 shares during the period. Belpointe Asset Management LLC acquired a new stake in Hims & Hers Health in the 3rd quarter valued at $76,000. Finally, Certuity LLC acquired a new stake in Hims & Hers Health in the 4th quarter valued at $109,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $12.36 on Friday. The company has a market capitalization of $2.65 billion, a PE ratio of -112.27 and a beta of 0.97. The company has a 50-day simple moving average of $14.04 and a two-hundred day simple moving average of $10.35. Hims & Hers Health has a one year low of $5.65 and a one year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm’s revenue was up 45.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.05) earnings per share. On average, equities analysts predict that Hims & Hers Health will post 0.11 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.